Neogen Corp (NEOG) FinancialsNEOGNeogen Corp

Neogen Corporation (NEOG) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Culture Media & Other, accounting for 38.5% of total sales, equivalent to $86.80M. Other significant revenue streams include Bacterial & General Sanitation and Genomics Services. Understanding this composition is critical for investors evaluating how NEOG navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Neogen Corporation maintains a gross margin of 37.59%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.38%, while the net margin is -5.02%. These profitability ratios, combined with a Return on Equity (ROE) of -0.38%, provide a clear picture of how effectively NEOG converts its operational activities into shareholder value.

In the context of the broader market, NEOG competes directly with industry leaders such as CDNA and ATRC. With a market capitalization of $2.52B, it holds a leading position in the sector. When comparing efficiency, NEOG's gross margin of 37.59% stands against CDNA's 73.50% and ATRC's 77.23%. Such benchmarking helps identify whether Neogen Corporation is trading at a premium or discount relative to its financial performance.

Neogen's Q4 revenue was $225.3 million, with a significant improvement in net loss, which was reduced to $11.3 million from a previous year's loss of $612.2 million. The company also reported a positive EBITDA of $31.2 million, indicating operational efficiency improvements.